Navigation Links
Long-Term 12-Month Safety Data Presented on ADHD Patch DAYTRANA(TM) (methylphenidate transdermal system)
Date:10/25/2007

Study Shows ADHD Patch Provides Tolerable and Effective Symptom Control

BOSTON, Oct. 25 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY, TSX: SHQ), the global specialty biopharmaceutical company, announced that data from a 12-month study of DAYTRANA(TM) (methylphenidate transdermal system), the Attention Deficit Hyperactivity Disorder (ADHD) patch, demonstrated that DAYTRANA provided significant ADHD tolerability and symptom control improvement in children aged 6 to 12 years. The study data was presented today at a major scientific and educational meeting of child and adolescent psychiatrists held in Boston, and is consistent with data previously presented.

"In our study, children with ADHD experienced effective ADHD symptom control improvement when using DAYTRANA for 12 months, improving their ability to maintain focus and concentration in and outside of the classroom," reported investigator Frank A. Lopez, M.D., neurodevelopmental pediatrician at the Children's Developmental Center, Winter Park, Fla. "Importantly, this year- long study showed that DAYTRANA maintained a favorable safety profile throughout the study period, with adverse events consistent with previous DAYTRANA studies."

Shire's DAYTRANA is the first and only patch medication approved by the U.S. Food and Drug Administration (FDA) to treat the symptoms of ADHD in children aged 6 to 12 years. The study results demonstrate that adverse events associated with DAYTRANA were similar to other methylphenidate products. The most common adverse events reported in this study were decreased appetite, headache, upper respiratory tract infection, cough, fever, and decreased weight. When worn for the recommended nine hours, efficacy has been demonstrated from the first time point measured (two hours) through the 12-hour time point. Because DAYTRANA is a patch, physicians may recommend that patients shorten the wear time if shorter duration of effect is desired or to help manage
'/>"/>

SOURCE Shire plc
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Anesiva Announces Phase 2 Data Showing Substantial, Long-Term Pain Reductions with Adlea(TM) (formerly 4975) in Osteoarthritis of the Knee
2. Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival
3. 8-Year Long-term Data Demonstrate Prolonged Overall Survival and Length of Disease Remission with Bexxar
4. Surfaxin (Lucinactant) Long-Term Survival Advantage vs. Comparators Published in Pediatrics
5. Vaxfectin-formulated Measles DNA Vaccine Elicits Long-term Protection and Sterilizing Immunity in Nonhuman Primates
6. Long-Term Extension of Ulcerative Colitis Study Shows Remicade Responders Maintained Improvement Through Two Years of Follow-Up
7. New Long-Term Data Analyses for Bifeprunox Show Favorable Effects Versus Placebo in Stabilized Patients with Schizophrenia
8. Medtronic Updates Long-Term ENDEAVOR I-II Clinical Data Showing Sustained Safety and Significant Reductions in Repeat Procedures
9. Taxus VI Clinical Trial Demonstrates Positive Long-Term Outcomes for Moderate-Release Paclitaxel-Eluting Stent at Four Years
10. UCB Presents Long-Term CImzia Data in Crohns Disease
11. PDL BioPharma Announces Long-Term Nuvion Data Presented at 2007 Digestive Disease Week

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...N.J.,Nov.25/PRNewswire/--RegadoBiosciences,aprivat...captamerswithactivecontrolagents,announcedthatDavi...perJaffray21stAnnualHealthCareConferenceattheNewYo...illbegivenat1:10pm(EST)onTuesday,December1andwilli...ontheleaddevelopmentprogram,theanticoagulantsystem...
(Date:11/25/2009)...5/PRNewswire/--Reportlinker.comannouncesthatanewma... MammographyEquipment-AGlobalMarketPerspective ...graphy-Equipment---A-Global-Market-Perspective.htm...izedaswellasdevelopingnationsisaprincipalfactorinf...latingawarenessaboutbreastcancerhasallowedwomentoc...
(Date:11/25/2009)...,Nov.25/PRNewswire/--AccordingtoMillenniumResearch...rketintelligence,thenearly$3billionUSmarketfortrau...henextfiveyearsdespitetherecenteconomicslowdown.MR...tthismarketwillremainhighlydynamicoverthenextfivey...npreviouslyunderservedsegmentsofthetraumafixationm...
Breaking Medicine Technology:Regado Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference on December 1, 2009 2Reportlinker Adds Mammography Equipment - A Global Market Perspective 2Reportlinker Adds Mammography Equipment - A Global Market Perspective 3Reportlinker Adds Mammography Equipment - A Global Market Perspective 4Reportlinker Adds Mammography Equipment - A Global Market Perspective 5Reportlinker Adds Mammography Equipment - A Global Market Perspective 6Reportlinker Adds Mammography Equipment - A Global Market Perspective 7US Trauma Fixation Device Market Not Seeing Signs of Slowdown 2US Trauma Fixation Device Market Not Seeing Signs of Slowdown 3Indiana University receives NIH grant to improve health care in East Africa 61442 1Indiana University receives NIH grant to improve health care in East Africa 61442 2Indiana University receives NIH grant to improve health care in East Africa 61442 3Scientists guide immune cells with light and microparticles 10745 1Scientists guide immune cells with light and microparticles 10745 2New research provides insights into potential ecological costs and cobenefits of REDD 10742 1New research provides insights into potential ecological costs and cobenefits of REDD 10742 2New research provides insights into potential ecological costs and cobenefits of REDD 10742 3
... -, PRINCETON, N.J. and SAN DIEGO, Aug. 18 Tobir...y company committed to the,research and product di...,infectious diseases, today announced the issuance... Trademark Office, covering the use of TBR-652, a,...or the treatment of HIV-1,infection in adults., T...
...Newswire-FirstCall/ -- Pharmaxis,(ASX: PXS; Nasdaq...se 3,clinical trial of Bronchitol for the treatmen...e first efficacy data from the trial is expected t...trial commenced its dosing phase in,April 2007, re...ts in June,2008 and closed today with 325 subjects...
Other Medicine Technology:Bronchitol Phase 3 Cystic Fibrosis Trial Completes Recruitment 2
(Date:11/25/2009)...hanksgivingmealswillbedeliveredtoapproximately1,00...FaithInAction/VolunteerActionforAging,aprogramoper...hPlan.Formorethan17yearstheseorganizationshavegath...ealstoseniorsinneedinLongBeach,Lakewood,SignalHill..., "Ourwarmholidaymealsaredeliveredtopeoplewhohave...
(Date:11/25/2009)...e/--TheBlackAIDSInstituterecentlyheldBoardofDirect...,, ThenewBoardMembersareahighlydiversegroupofle...ernmenthealthprograms,editorial,andbusinessentrepr...lbackgroundsincludingbothheterosexualandgayBlackme...ingmultipleagegroups. ,, (Photo: http://www.new...
(Date:11/25/2009)...ndPressJoinEfforttoEducate ,, MEMPHIS,Tenn.,No...BipolarFoundationandtheMedicAlertFoundationreceive...,whichisnowbeingwidelyacceptedasapreventivehealthc...larFoundationreceivedaproclamationofendorsementvia...sianaMitchLandrieu.TheNationalBipolarFoundationsta...
(Date:11/25/2009)...ically significant survival benefit from adjuvant ...ER)-positive tumors had high levels of phosphoryla... according to a brief communication published onli...cer Institute . , Approximately 50% of breast ca...tudies have shown that ER-alpha S118-P is required...
(Date:11/25/2009)...imple question has been the focus of intense resea...ates High Blood Pressure in Mice & Men, Does stre...has been the focus of intense research for many ye...blished a link between a novel gene, phosducin, an... well as humans. The studies were directed by scie...
Breaking Medicine News(10 mins):Health News:SCAN Employees and Community Volunteers to Help Deliver One Thousand Thanksgiving Meals to Homebound Seniors 2Health News:Black AIDS Institute Announces 2010 Board Election Results 2Health News:First Time-Door is Open for Family Discussion of Bipolar Disorder 2Health News:First Time-Door is Open for Family Discussion of Bipolar Disorder 3Health News:New stress-related gene modulates high blood pressure in mice and men 2
... a recent study conducted by researchers at Wake F...gues show that cognitive functioning abilities dro...h type 2 diabetes. , The study appears in this mo...rial (ACCORD), found a statistically significant i...
...French . , Montreal, February 11th, 2009 - The ...nt on the nutrients the tumours receive through th...ch Institute of the McGill University Health Centr... stimulate the growth of the blood vessels that fe...
...rld,s first phase one FDA-approved clinical trial ...ase will be conducted by a team of University of ...he first time, patients with advanced heart diseas...ent,s own cardiac tissue. During surgery, a small ...
... Abbott ( NYSE: ABT ),today announced it received...nistration (FDA) for its new, compact hematology i...N Emerald will expand the company,s hematology,pla...ries and clinics continue to seek,greater efficien...
...ges Prevention Through Screenings , ...-- What better time than February, National Cancer...r health is in their own hands? ZocDoc, the servic... month. Now more than ever, New Yorkers are able t...
...ves better predictor than PSA, study says , ...g for changes in the number of circulating tumor c...ostate cancer patients, survival and response to t...ors such as changes in levels of prostate-specific...
Other Medicine News:Health News:Higher blood sugar levels linked to lower brain function in diabetics, study shows 2Health News:Innovative method to starve tumors 2Health News:World's First Cardiac Adult Stem Cell Trial to Take Place in Louisville 2Health News:Abbott Receives FDA Clearance for New CELL-DYN(R) Emerald(TM) Hematology Instrument 2Health News:Abbott Receives FDA Clearance for New CELL-DYN(R) Emerald(TM) Hematology Instrument 3Health News:ZocDoc Joins the Fight Against Cancer 2Health News:Levels of Circulating Tumor Cells Could Predict Prostate Cancer Outcome 2
...matology control, offers complete assay values for...ith the Coulter GENS, STKS, MAXM and HmX. This uni...y closed-vial stability and is available in low, n...al is compatible with all cassette systems. Barcod...
Antelys Peek Lumbar Technologies
D-SPECT Cardiac Imaging System
Placemark
Medicine Products: